Biomarker May Predict Prostate Cancers Requiring Treatment
Researchers have now identified a 3-gene signature that could indicate whether a particular early-stage prostate cancer is indolent. The test relies on a tissue sample, a PSA test, and a histology assessment. (Source: Cancer Network)
Source: Cancer Network - September 11, 2013 Category: Cancer & Oncology Source Type: news

Nine of Ten Women Cannot Quantify Lifetime Breast Cancer Risk
More than 90% of women about to undergo a mammography were unable to accurately quantify their risk for breast cancer, either over- or underestimating their risk, according to the results of a large-scale survey presented at the ASCO Breast Cancer Symposium 2013. (Source: Cancer Network)
Source: Cancer Network - September 10, 2013 Category: Cancer & Oncology Source Type: news

After Radiation for DCIS, No Increase in Cardiovascular Mortality, Morbidity
The exposure of the heart to radiation during radiotherapy for ductal carcinoma in situ (DCIS) did not increase cardiovascular mortality or morbidity, according to a study by researchers in the Netherlands. (Source: Cancer Network)
Source: Cancer Network - September 10, 2013 Category: Cancer & Oncology Source Type: news

Lightly Pigmented Skin Lesion on 35-Year-Old Patient
A 35-year-old man presented with a lightly pigmented lesion on the skin of the right arm. Complete surgical excision of the lesion was performed. What is your diagnosis? (Source: Cancer Network)
Source: Cancer Network - September 9, 2013 Category: Cancer & Oncology Source Type: news

Batch MRI Breast Cancer Screening Possibility with Accelerated Protocol
Expert radiologists were able to screen magnetic resonance images and rule out breast cancer diagnosis with a negative predictive value of about 99% using an abridged breast MRI protocol in a single-center study presented Saturday at the ASCO Breast Cancer Symposium 2013. (Source: Cancer Network)
Source: Cancer Network - September 9, 2013 Category: Cancer & Oncology Source Type: news

Promising Marker for Response to EGFR Inhibitors
The ratio of two protein levels may predict clinical benefit of EGFR inhibitors. Low levels of a protein called Mig6 (mitogen-inducible gene 6) and high levels of EGFR corresponded to a higher clinical response rate and progression-free survival in a small prospective cohort of lung cancer patients treated with the anti-EGFR therapy gefitinib. (Source: Cancer Network)
Source: Cancer Network - September 9, 2013 Category: Cancer & Oncology Source Type: news

Multiple Myeloma Patients Had Continued Response to ASCT Past 100-Day Disease Assessment
Patients with multiple myeloma who underwent autologous stem cell transplantation may have a continued response to the treatment even after the traditional disease assessment at 100 days. A new study indicates that this continued response maintained prognostic value and should be taken into account when considering post-transplant therapies. (Source: Cancer Network)
Source: Cancer Network - September 8, 2013 Category: Cancer & Oncology Source Type: news

Identifying Indolent vs Potentially Aggressive DCIS, More Research Needed
As part of our coverage for the ASCO Breast Cancer Symposium 2013, we spoke with Dr. Susan K. Boolbol, chief of the division of breast surgery at the Appel-Venet Comprehensive Breast Service at Beth Israel Medical Center in New York City, who is chairing a general session panel discussion on the overdiagnosis of breast cancer. (Source: Cancer Network)
Source: Cancer Network - September 7, 2013 Category: Cancer & Oncology Source Type: news

Smoke Alarm! Is It Now OK to Smoke?
How long ago did we learn that smoking caused lung cancer? The USPSTF is poised to recommend annual screening CT scans for the detection of lung cancer in high risk individuals. Are there enough CT scanners to handle the volume? The LLC’s are forming now to put a dedicated lung screening CT machine next to every convenience store. Get your carton and CT in one stop! (Source: Cancer Network)
Source: Cancer Network - September 7, 2013 Category: Cancer & Oncology Source Type: news

Carbon Ion Radiotherapy Works for Spinal Sarcoma
Carbon ion radiotherapy is a safe and effective method for treating unresectable spinal sarcomas, according to a retrospective analysis from one center in Japan. (Source: Cancer Network)
Source: Cancer Network - September 6, 2013 Category: Cancer & Oncology Source Type: news

Night Shifts Implicated in Increased Prostate Cancer Risk
Shift work is positively associated with higher levels of prostate-specific antigen (PSA) levels in men between the ages of 40 and 65, according to results of a new study. (Source: Cancer Network)
Source: Cancer Network - September 5, 2013 Category: Cancer & Oncology Source Type: news

Extensive Hair Loss Following Second Round of Chemotherapy
A 65-year-old man experienced extensive hair loss following the second round of a chemotherapeutic regimen. The alopecia ultimately evolved into total hair loss, although near total recovery occurred about 4 months following cessation of chemotherapy. What drug is most likely responsible for this degree of hair loss? (Source: Cancer Network)
Source: Cancer Network - September 4, 2013 Category: Cancer & Oncology Source Type: news

Notch1 Regulates Tumor Formation, Possible Lung Cancer Target
Bench and mouse studies have shown that the Notch1 gene is a crucial contributor to tumorigenesis in non-small-cell lung cancer (NSCLC). It aids tumor initiation by suppressing apoptosis, or programmed cell death, which is regulated by p53. (Source: Cancer Network)
Source: Cancer Network - September 4, 2013 Category: Cancer & Oncology Source Type: news

HER2-Positive Breast Cancer Patients Prefer Subcutaneous Trastuzumab
Results of the PrefHer study indicated that when given the option between subcutaneous trastuzumab and intravenous trastuzumab, significantly more patients with HER2-positive breast cancer preferred the subcutaneous administration. (Source: Cancer Network)
Source: Cancer Network - September 3, 2013 Category: Cancer & Oncology Source Type: news

Aggressiveness of Prostate Tumors May Not Change as Cancer Evolves
Prostate tumors may not readily evolve from low to high grade, according to a new study. The results have important clinical implications for patients and clinicians when choosing active surveillance or treatment. (Source: Cancer Network)
Source: Cancer Network - September 2, 2013 Category: Cancer & Oncology Source Type: news